Daniel D. Shoemaker
2017
In 2017, Daniel D. Shoemaker earned a total compensation of $798.3K as Chief Scientific Officer at Fate Therapeutics, a 12% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $80,194 |
|---|---|
| Option Awards | $365,604 |
| Salary | $352,500 |
| Total | $798,298 |
Shoemaker received $365.6K in option awards, accounting for 46% of the total pay in 2017.
Shoemaker also received $80.2K in non-equity incentive plan and $352.5K in salary.
Rankings
In 2017, Daniel D. Shoemaker's compensation ranked 10,043rd out of 14,666 executives tracked by ExecPay. In other words, Shoemaker earned more than 31.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,043 out of 14,666 | 32nd |
Division Manufacturing | 3,879 out of 5,768 | 33rd |
Major group Chemicals And Allied Products | 1,356 out of 2,074 | 35th |
Industry group Drugs | 1,100 out of 1,730 | 36th |
Industry Biological Products, Except Diagnostic Substances | 198 out of 316 | 37th |
Source: SEC filing on March 16, 2018.
Shoemaker's colleagues
We found two more compensation records of executives who worked with Daniel D. Shoemaker at Fate Therapeutics in 2017.